Aristocrat Leisure stock rises on A$750 million buyback extension as investors eye next AGM
10 January 2026
1 min read

Aristocrat Leisure stock rises on A$750 million buyback extension as investors eye next AGM

SYDNEY, January 10, 2026, 17:50 (AEDT) — Market closed

  • Aristocrat lifts on-market buyback cap by A$750 mln, taking total authorisation to A$1.5 bln through March 2027
  • Shares ended Friday up 1.0% at A$57.22
  • Focus shifts to buyback pace and the Feb. 19 AGM for the next update

Aristocrat Leisure Ltd (ASX:ALL) shares closed 1.0% higher on Friday after the gaming supplier widened its on-market share buy-back, ending at A$57.22. (Aristocrat)

That matters now because a buy-back reduces the number of shares on issue, which can lift earnings per share over time, and it can also flag confidence about cash flow. The move came as the S&P/ASX 200 finished little changed, leaving room for stock-specific news to steer the tape. (Yahoo Finance)

Aristocrat said it has repurchased A$701.1 mln of shares since February 2025 and now has approval to buy back up to a further A$750 mln, stretching the program to March 5, 2027 and lifting total capacity to A$1.5 bln. In an on-market buy-back, a company buys shares on the stock exchange. Chief Executive Trevor Croker said the group could keep “a mix of returns to shareholders via dividends and share buy-backs” while still investing for growth.

At Friday’s close, Aristocrat had a market value of about A$35.3 bln, putting the fresh A$750 mln headroom a little over 2% of that. The stock opened at A$57.18, hit A$58.50 and traded as low as A$57.16, levels traders often watch for near-term resistance and support. (Intelligent Investor)

Citi analyst Adrian Lemme said the expansion, with roughly A$50 mln left under the earlier authorisation, was bigger than expected, Sharecafe reported. Citi lifted earnings-per-share forecasts — profit per share — by up to 1% for fiscal 2026 to 2028 and kept a “buy” rating with a A$71 target price, the report said.

Aristocrat sells slot machines and casino systems and also runs digital gaming operations, which can make its earnings sensitive to offshore demand and currency swings. Rivals include Light & Wonder and International Game Technology.

But the buy-back is not a promise. The board can slow or halt purchases if market conditions turn, if cash is redirected to a deal, or if demand softens in key gaming markets.

With the ASX shut for the weekend, traders will watch for signs of buy-back activity when regular trading resumes on Monday. The next scheduled milestone on market calendars is Aristocrat’s annual general meeting on Feb. 19. (Market Index)

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Tunbridge Wells taps wobble again: South East Water targets Jan 13 fix as MPs press for answers
Previous Story

Tunbridge Wells taps wobble again: South East Water targets Jan 13 fix as MPs press for answers

Mineral Resources stock rises after director share filings as Jan 29 update nears
Next Story

Mineral Resources stock rises after director share filings as Jan 29 update nears

Go toTop